Commit To Purchase Inhibrx Biosciences At $50, Earn 16.7% Annualized Using Options

The piece evaluates selling a Jan 2027 $50 put on Inhibrx Biosciences (INBX), noting the stock trades at $73.22 and the $8 premium nets a 16.7% annualized return for the put seller. Assignment would only occur if shares fall ~31.7%, producing an effective cost basis of $42.00 (strike minus premium); trailing-12-month volatility is 95%, highlighting elevated risk. The analysis frames the trade as premium collection with limited upside relative to owning shares and emphasizes using price history and volatility alongside fundamentals to assess reward versus risk.

Analysis

Market structure: The immediate beneficiaries are option premium collectors, brokers and market‑makers capturing elevated bid/ask spreads; losers are naked put sellers who get assigned into a volatile biotech name. INBX’s 95% trailing vol and a quoted Jan‑2027 $50 put that nets to $42 on assignment ($8 premium) signal market demand for income and protection rather than confidence in fundamentals, compressing effective float only if large volumes force assignment.

Risk assessment: Tail risks are classic biotech binaries — negative trial data, FDA rejection or forced equity raises that can erase >50% in weeks; with 95% vol the one‑year probability of breaching $50 is material (~45–55% under simple lognormal assumptions). Near term (days–weeks) the trade is dominated by IV and upcoming catalyst windows, medium term (months) by cash runway/financing risk, long term (quarters–years) by clinical readouts and commercialization outcomes.

Trade implications: For yield seekers, cash‑secured Jan‑2027 $50 puts on INBX offer ~16.7% annualized if you are willing to own at $42; defined‑risk structures (50/35 put spreads) truncate tail risk and should be preferred for >1% position sizes. Pair trades — long INBX vs short IBB (0.5x) — hedge sector beta; if holding shares buy OTM protection (buy Jan27 $80 calls if bullish or buy $35 puts if protecting assignment) and trim on IV collapse >30%.

Contrarian angles: Consensus frames this as an attractive yield trade but underestimates binary downside and dilution probability; premium may undercompensate for a >50% drawdown scenario common in small‑cap biotechs. Historically similar names suffer severe repricing after one negative readout — favor defined‑risk or small, disciplined sizing rather than naked exposure and watch financing covenants which can force selling into illiquid markets.

Key Decisions for Investors

• Sell cash‑secured INBX Jan‑2027 $50 puts sized to 1–2% of portfolio only if comfortable owning shares at net $42 (strike $50 minus $8 premium); treat realized annualized yield target ~16.7%, and set a liquidity/assignment plan in advance (prepare to hold or hedge if assigned).
• Prefer a defined‑risk alternative: implement a Jan‑2027 bull put spread by selling the $50 put and buying the $35 put (size 1–2% of portfolio); this caps max loss at $15 minus net credit — size so max loss ≤2% portfolio.
• If you want directional exposure with sector hedge: go long INBX equity or LEAPS (size 0.5–1%) while shorting IBB at 0.5x notional to remove sector beta; exit/rebalance 30 days before any INBX clinical readout or if INBX rises >40% from current $73.22 (take profits).
• Avoid naked short‑put positions if INBX implied volatility >90% and there is a known clinical or financing catalyst within 90 days; if holding short puts, buy downside protection if price falls to or below $50 or if IV spikes another 20–30%.